auto_awesome_motion View all 3 versions
organization

WITS HEALTH CONSORTIUM(PTY) LTD

Country: South Africa
9 Projects, page 1 of 2
  • Open Access mandate for Publications
    Funder: EC Project Code: 852787
    Overall Budget: 1,499,840 EURFunder Contribution: 1,499,840 EUR
    Partners: University of Edinburgh, UNIVERSITY OF THE WITWATERSRAND JOHANNESBURG, WITS HEALTH CONSORTIUM(PTY) LTD

    Violence Violence is an important societal challenge and associated with poor health outcomes across the life-course. Studies find consistent associations between childhood violence exposure and risk for victimisation and perpetration in adulthood, particularly across generations. Thus far, we lack an evidence-base to understand the underlying mechanisms of intergenerational violence transmission as well as potential for prevention in regions with high rates of interpersonal violence such as sub-Saharan Africa. This marks a major evidence gap and a compelling need. This study will use a mixed methods approach to develop the first-known empirically-generated theoretical framework on intergenerational violence transmission. It will do so using three approaches never utilised in the region: 1) using data from a 1-year longitudinal study of 1800 adolescents in South Africa (interviewed in 2010/11 and 2011/2012) it will re-trace original participants, re-interview them as young adults aged 20-27, recruit their children (n~211) and previous primary caregivers (n~540) and conduct in-depth qualitative work on a sub-sample of families to identify mechanisms of violence transmission across generations and genders, 2) it will investigate the effect of the prevalent structural risk factors poverty, poor service access and delivery and the HIV epidemic on violence transmission, and 3) it will examine the effect of protective interventions and policies using quasi-experimental methods. This study will transform our understanding of the causes, effects and potential prevention mechanisms of intergenerational violence transmission through cutting-edge social science research. This is an ambitious research agenda of a complex behaviour and is characterised by methodological and theoretical innovation never used in the region before. The methodology presents high risks balanced by the potential for ground-breaking scientific and social impact for violence research and prevention.

  • Funder: EC Project Code: 294557
    Partners: UOXF, McGill University, WITS HEALTH CONSORTIUM(PTY) LTD, RIVM
  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 847762
    Overall Budget: 6,388,100 EURFunder Contribution: 6,388,100 EUR
    Partners: CNRS, NCTLD, IGTP, LIO, WITS HEALTH CONSORTIUM(PTY) LTD, Leiden University Medical Center, Oslo University Hospital, ANAXOMICS BIOTECH, S.L., TES2A

    Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsible infective strain and very costly in drug-resistant cases (MDR-TB). The European Region still has the highest prevalence of MDR-TB in the world. Host-Directed Therapies (HDT) have been recently proposed to shorten treatment length and by to improve the patients’ outcomes while not increasing the risk of generating drug resistance. As hyperinflammation is responsible of the lung damage associated to patients’ worse outcomes and sequelae, one of the approaches is to add an HDT with anti-inflammatory effect to the current drug regimen to cure the patients faster while having less permanent lung damage. Because TB has a wide range of clinical forms and severity stages, any therapeutic regimen needs to be studied in clinical trials (CT) as its benefit might differ among patients. No individualized personalized medicine is possible without stratifying the patients by integrating pathogen and host factors that will predict the course of the disease and the response to the intervention. SMA-TB objectives are: • To evaluate in a CT the potential impact of acetylsalicylic acid (ASA) and Ibuprofen (Ibu) (anti-inflammatoriesy HDT) as adjuncts to standard therapy for drug sensitive (DS-) and MDR-TB. This potentially will reduce tissue damage, decrease the length of the treatment and the risk of bad outcomes. • To identify and clinically validate host and pathogen biomarkers for further selection according to their relevance in terms of their ability to predict TB course and outcomes and response to treatment thanks to data science protocol. • To generate a medical algorithm to stratify patients using network-based mathematical modelling for predicting the course of the disease and its response to the intervention, to be applied during clinical management to improve and personalize TB.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101057843
    Overall Budget: 8,759,070 EURFunder Contribution: 8,759,070 EUR
    Partners: KI, DTU, University of Graz, AGA KHAN HEALTH SERVICE, KENYA, WHO, Ghent University, CeSHHAR, LUNDS UNIVERSITET, WITS HEALTH CONSORTIUM(PTY) LTD

    There are major gaps in surveillance of climate change and health in the EU and globally, making it difficult to track health burdens and policy outcomes. The HIGH Horizons project, over four years, involves 5 partners in the EU, 3 in Africa and 2 international organisations (WHO and UNICEF). It centres on pregnant and postpartum women, infants, and health workers, groups heavily affected by climate change. We quantify and monitor direct and indirect health impacts of extreme heat; test a personalised Early Warning System (EWS); and implement integrated adaptation-mitigation actions in health facilities. Analyses of heat impacts and data science predictive modelling using data from Sweden; Lazio Italy, and health facilities in Kenya and South Africa underpin all activities. These analyses and systematic reviews inform testing and selection of global, EU and national indicators. Analyses also inform cut-off thresholds for EWSs, stratified by risk groups. A smartphone app (ClimApp-MCH) will deliver warnings and setting-specific messages, co-designed locally. The app will be evaluated among 200 mothers and infants in Sweden, South Africa and Zimbabwe, from antepartum through 12 months of infant age. Simultaneously, we will document impacts of heat exposure on health worker wellbeing, health, productivity and quality of care, including through time-motion studies. Modifications to health facilities will be co-designed and modelled to reduce heat exposure for health workers and to limit facilities carbon emissions. Health worker outcomes and facility emissions will be compared pre- and post-intervention. Analyses weighing costs and benefits cut across all activities. Throughout we will disseminate project findings to relevant stakeholders, prioritising EU and global policy makers and leveraging existing networks. The final set of indicators on climate change and maternal, newborn and child health will be released in a WHO, UNICEF and UNFPA guidance document. In order to optimise synergies, avoid overlaps and increase the impact of the projects selected for funding from the call HORIZON-HLTH-2021-ENVHLTH-02-03 (Health impacts of climate change, costs and benefits of action and inaction, Horizon Europe projects 101057843 HIGH Horizons, 101057131 CATALYSE, 101057764 BlueAdapt, 101057690 CLIMOS, 101057554 IDAlert and 101057739 TRIGGER), the projects will form a cluster. Common cluster activities will include the following: 1 . Common kick-off meeting of the six projects, to be organized in cooperation between DG R&I and the cluster; 2. Annual cluster meetings and periodic report of joint activities (delivered at each reporting period); 3. Common dissemination and communication activities, including a common dissemination and communication strategy for the cluster, cluster web portal and visual identity, cluster brochure, cluster newsletters, stakeholder list, Shared individual Data Management Plans between cluster partners, Policy Strategy of the cluster, including joint policy briefs and Scientific strategy of the cluster. The penholder and project responsible for each joint deliverable will be decided in the document setting out the Modalities for Implementation of the Cluster to be agreed on during 2022. 4. Thematic workshops/trainings on issues of common interest to be defined in the context of the scientific strategy of the cluster; 5. Working groups on topics of common interest (e.g., data management, communication and dissemination, science-policy link): to be defined in the context of the scientific strategy of the cluster;

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 847465
    Overall Budget: 9,969,010 EURFunder Contribution: 9,969,010 EUR
    Partners: University of Antwerp, LMU MUENCHEN, THE AURUM INSTITUTE NPC, Institutul de Pneumoftiziologie "Marius Nasta", FZB, NCTLD, IFP CHIRIL DRAGANIUC, WITS HEALTH CONSORTIUM(PTY) LTD, INS, SWISS TPH

    Tuberculosis is a leading cause of morbidity and mortality worldwide. Current TB treatments are inadequate, requiring patients closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated. These concerns are greatly magnified in rifampicin-resistant (RIF-R) TB, an urgent global and EU public health priority. WHO estimates that only 54% of patients who began RIF-R TB treatment in 2016 were cured. In addition to these well-recognized shortcomings, current TB treatments, particularly those for RIF-R TB, leave a majority of cured patients with permanent, clinically significant lung impairment and radiographic evidence of bronchiectasis and fibrosis. This project will determine if two adjunctive host-directed therapies (HDTs) can prevent these poor outcomes. 330 patients with RIF-R TB and baseline risk factors for poor outcome will be enrolled in a randomized, controlled, 3-armed multi-centre trial, with clinical sites in Germany, Romania, Moldova, Georgia, Mozambique, and South Africa. All patients will receive standard multidrug therapy according to national guidelines. Those patients randomized to the experimental arms will in addition receive either CC-11050 or metformin. These selected HDT candidates represent 2 complementary HDT strategies: reducing inflammation vs inducing host cell anti-microbial activity, respectively. Both candidates are supported by data from preclinical and clinical studies. Co-primary efficacy endpoints will examine effects on lung function (measured by spirometry) and infection (measured as time to stable sputum culture conversion). A sub-study will examine quantitative change in lung radiodensity by CT scan. If successful, this ground-breaking project will increase Europe’s capacity to control RIF-R-TB by developing new treatments that increase the likelihood of cure and reduce the risk of life-long disability.